An average of 20% of sham-treated CD8+ TILs from LL2/Ctrl tumors and 15% from LL2/B3a tumors showed IFN-γ production, whereas the frequencies of IFN-γ–producing CD8+ TILs were reduced with tumor growth in both groups (Figure 4E). The gene discussed is CD8A; the disease is neoplasm.